Log in

NASDAQ:CEMIChembio Diagnostics Stock Price, Forecast & News

$4.18
+0.90 (+27.44 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.50
Now: $4.18
$4.38
50-Day Range
$3.18
MA: $8.01
$12.53
52-Week Range
$2.25
Now: $4.18
$15.89
Volume22.19 million shs
Average Volume1.56 million shs
Market Capitalization$84.31 million
P/E RatioN/A
Dividend YieldN/A
Beta2.26
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue virus, chikungunya virus, ebola, lassa, marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. In addition, the company develops tests for a specific form of cancer, concussion, and bovine tuberculosis; and handheld optical analyzers for rapid diagnostic tests. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; Foundation for Innovative New Diagnostics to develop a POC fever panel assay for life-threatening acute febrile illnesses; AstraZeneca to develop a POC test for eosinophilic respiratory disease; and LumiraDx to develop POC diagnostic tests for infectious diseases. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 4.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CEMI
CUSIPN/A
Phone631-924-1135

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.46 million
Book Value$1.37 per share

Profitability

Net Income$-13,680,000.00

Miscellaneous

Employees295
Market Cap$84.31 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for CEMI and its competitors with MarketBeat's FREE daily newsletter.

Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

How has Chembio Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Chembio Diagnostics' stock was trading at $3.10 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CEMI shares have increased by 34.8% and is now trading at $4.18. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Chembio Diagnostics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last year. There are currently 5 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Chembio Diagnostics.

When is Chembio Diagnostics' next earnings date?

Chembio Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Chembio Diagnostics.

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics Inc (NASDAQ:CEMI) released its quarterly earnings data on Monday, May, 4th. The company reported ($0.25) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.02. The firm earned $6.86 million during the quarter. Chembio Diagnostics had a negative return on equity of 63.13% and a negative net margin of 48.02%. View Chembio Diagnostics' earnings history.

What price target have analysts set for CEMI?

5 analysts have issued 1 year price targets for Chembio Diagnostics' shares. Their forecasts range from $4.00 to $8.00. On average, they anticipate Chembio Diagnostics' stock price to reach $6.50 in the next year. This suggests a possible upside of 55.5% from the stock's current price. View analysts' price targets for Chembio Diagnostics.

What are Wall Street analysts saying about Chembio Diagnostics stock?

Here are some recent quotes from research analysts about Chembio Diagnostics stock:
  • 1. According to Zacks Investment Research, "CHEMBIO DIAGNOSTICS, INC. develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the growing $5 billion point-of-care testing market. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by a third party company. Chembio markets its HIV STAT-PAK line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio also has rapid tests for veterinary tuberculosis and chagas disease. In 2007 Chembio received a U.S. patent for its Dual Path Platform technology which has significant advantages over lateral-flow technologies. This technology is providing Chembio with a significant pipeline of business opportunities for the development and manufacture of new products based on DPP. Chembio is licensed by the U.S. Food and Drug Administration as well as the U. S. Department of Agriculture, and is certified for the global market under the International Standards Organization directive 13.485. " (6/19/2020)
  • 2. Canaccord Genuity analysts commented, "We recently hosted Chembio CEO John Sperzel for two days of investor meetings. We believe Chembio possesses an underappreciated, compelling diagnostics platform that can be used for many new indications. For small cap mandates, we recommend investors get to know Chembio (at our conference on August 7th) as they target 25% top line revenue CAGR (through 2023) and materially improve GMs over the next 1-3 years. Trading at just 2.2x (vs. 4.6x peer average) our 2020 rev. estimate of $44M, we believe CEMI is an underappreciated small-cap growth stock, given its best-in-class test accuracy, unique ability to multiplex, and ability to provide quantitative results. We see upside from a number of global collaborations. We reiterate our BUY rating and $10 PT. HIV syphilis approval is a key 2H/19 catalyst." (7/22/2019)

Has Chembio Diagnostics been receiving favorable news coverage?

Press coverage about CEMI stock has trended somewhat negative this week, according to InfoTrie. The research group ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chembio Diagnostics earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Chembio Diagnostics.

Are investors shorting Chembio Diagnostics?

Chembio Diagnostics saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 1,430,000 shares, an increase of 49.4% from the May 31st total of 957,000 shares. Based on an average daily volume of 1,350,000 shares, the short-interest ratio is currently 1.1 days. Currently, 8.5% of the company's shares are sold short. View Chembio Diagnostics' Current Options Chain.

Who are some of Chembio Diagnostics' key competitors?

What other stocks do shareholders of Chembio Diagnostics own?

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the following people:
  • Mr. John J. Sperzel III, Pres, CEO & Director (Age 55)
  • Mr. Neil A. Goldman, Exec. VP & CFO (Age 51)
  • Mr. Javan Esfandiari, Chief Science & Technology Officer and Exec. VP (Age 52)
  • Dr. Robert Passas Ph.D., Sr. VP & Chief Commercial Officer (Age 65)
  • Mr. David A. Gyorke, Sr. VP & COO (Age 59)

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $4.18.

How big of a company is Chembio Diagnostics?

Chembio Diagnostics has a market capitalization of $84.31 million and generates $34.46 million in revenue each year. The company earns $-13,680,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Chembio Diagnostics employs 295 workers across the globe.

What is Chembio Diagnostics' official website?

The official website for Chembio Diagnostics is www.chembio.com.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 555 WIRELESS BLVD., HAUPPAUGE NY, 11788. The company can be reached via phone at 631-924-1135 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.